Trial Profile
Randomised phase II trial of Cediranib and Olaparib Maintenance in advanced/recurrent Cervical Cancer (COMICE)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms COMICE
- 01 Jul 2023 Status changed from active, no longer recruiting to completed.
- 14 Nov 2022 Status changed to active, no longer recruiting.
- 14 Nov 2022 Planned End Date changed from 1 Sep 2021 to 30 Jun 2023.